Human Type 3 3α-Hydroxysteroid Dehydrogenase (Aldo-Keto Reductase 1C2) and Androgen Metabolism in Prostate Cells
The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.
Abstract
Human aldo-keto reductases (AKRs) of the AKR1C subfamily function in vitro as 3-keto-, 17-keto-, and 20-ketosteroid reductases or as 3α-, 17β-, and 20α-hydroxysteroid oxidases. These AKRs can convert potent sex hormones (androgens, estrogens, and progestins) into their cognate inactive metabolites or vice versa. By controlling local ligand concentration AKRs may regulate steroid hormone action at the prereceptor level. AKR1C2 is expressed in prostate, and in vitro it will catalyze the nicotinamide adenine dinucleotide (NAD+)-dependent oxidation of 3α-androstanediol (3α-diol) to 5α-dihydrotestosterone (5α-DHT). This reaction is potently inhibited by reduced NAD phosphate (NADPH), indicating that the NAD+: NADPH ratio in cells will determine whether AKR1C2 makes 5α-DHT. In transient COS-1-AKR1C2 and in stable PC-3-AKR1C2 transfectants, 5α-DHT was reduced by AKR1C2. However, the transfected AKR1C2 oxidase activity was insufficient to surmount the endogenous 17β-hydroxysteroid dehydrogenase (17β-HSD) activity, which eliminated 3α-diol as androsterone. PC-3 cells expressed retinol dehydrogenase/3α-HSD and 11-cis-retinol dehydrogenase, but these endogenous enzymes did not oxidize 3α-diol to 5α-DHT. In stable LNCaP-AKR1C2 transfectants, AKR1C2 did not alter androgen metabolism due to a high rate of glucuronidation. In primary cultures of epithelial cells, high levels of AKR1C2 transcripts were detected in prostate cancer, but not in cells from normal prostate. Thus, in prostate cells AKR1C2 acts as a 3-ketosteroid reductase to eliminate 5α-DHT and prevents activation of the androgen receptor. AKR1C2 does not act as an oxidase due to either potent product inhibition by NADPH or because it cannot surmount the oxidative 17β-HSD present. Neither AKR1C2, retinol dehydrogenase/3α-HSD nor 11-cis-retinol dehydrogenase is a source of 5α-DHT in PC-3 cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These enzymes preferably act as reductases in vivo since they have Kd values for NADPH in the nanomolar range, there is a high NADPH/NADP+ ratio within cells and NADPH inhibits the NAD+ dependent oxidation reactions at low μM concentrations”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [15]
In the citing paper
“In peripheral tissues, AKR1C enzymes act as 3-keto and 17-ketosteroid reductases to catalyze either the formation of the most potent androgen 5α-dihydrotestosterone (5α-DHT) or its inactivation to yield the inactive androgens 5α-androstane-3α,17β-diol (3α-Diol) or 5α-androstane-3β,17β-diol (3β-Diol)”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [15]
In the citing paper
“COS-1, PC-3 and LNCaP cells transfected with AKR1C2 were able to recapitulate this reaction”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [15]
In the citing paper
“AKR1C2 has the highest catalytic efficiency as a 3-ketosteroid reductase and catalyzes reduction of 5α-DHT to 3α-Diol”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [15]
In the citing paper
“AKR1C3 catalyzes the reduction of Δ4-androstene-3,17-dione to form the potent androgen testosterone (Kd = 10−9 M for AR) and the reduction of 5α-androstane-3,17-dione to yield the most potent androgen 5α-DHT (Kd =10−10 M for the AR).”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [15]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
LNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
Steroid 5α-reductase: two genes/two enzymes
Russell, D. W., & Wilson, J. D. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.000325 · Cited by 1,105
PENNING, T. M., BURCZYNSKI, M. E., JEZ, J. M., HUNG, C.-F., LIN, H.-K., MA, H., MOORE, M., PALACKAL, N., & RATNAM, K. (2000) · Biochemical Journal · doi:10.1042/bj3510067 · Cited by 649
Self-citationThe induction of prostatic hypertrophy in the dog with androstanediol.
Walsh, P. C., & Wilson, J. D. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108353 · Cited by 418
A new nomenclature for the aldo-keto reductase superfamily
Jez, J. M., Flynn, T. G., & Penning, T. M. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)84253-0 · Cited by 354
Self-citationThe clinical development of a 5α-reductase inhibitor, finasteride
Stoner, E. (1990) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(90)90487-6 · Cited by 224
Biswas, M. G., & Russell, D. W. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.25.15959 · Cited by 224
Hormones and Prostate Cancer: What's Next?
Hsing, A. W. (2001) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a000795 · Cited by 216
Lin, H.-K., Jez, J. M., Schlegel, B. P., Peehl, D. M., Pachter, J. A., & Penning, T. M. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.13.0026 · Cited by 194
Self-citationThe role of androgens and the androgen receptor in prostate cancer.
Debes, J. D., & Tindall, D. J. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00413-5 · Cited by 191
Research works printed but not linked: 3
- Griffiths, 1999, Aspects of the cell biology of prostate cancer, 51
- Barbier, 2000, Cellular localization of uridine diphosphoglucronsyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistichemistry., J Clin Endocrinol Metab, 85, 4819
- Peehl, 1992, Culture of human prostate epithelial cells, 159
Cited by
Items 101–136 of 136
Dozmorov, M. G., Yang, Q., Matwalli, A., Hurst, R. E., Culkin, D. J., Kropp, B. P., & Lin, H. K. (2007) · Genomic Medicine · doi:10.1007/s11568-008-9018-9 · Cited by 5
“Elevated steady state levels of these 3a-HSD transcripts have been demonstrated in primary cultures of human prostate cancer cells as compared to epithelial cells derived from normal prostate (Lin et al. 1997; Rizner et al. 2003).”
BackgroundMethodSelf-citationGuo, S., Chen, Y.-Z., Liu, L., Liu, R., Liang, Y.-J., Wen, D., Jin, J., Tang, L., Mai, H., & Chen, Q. (2022) · BMC Cancer · doi:10.1186/s12885-022-09924-3 · Cited by 6
“The expression of AKR1C2 also increases both non-small cell lung cancer and prostate cancer [15, 16].”
BackgroundAtsriku, C., Hoffmann, M., Moghaddam, M. F., Kumar, G. N., & Surapaneni, S. (2014) · Xenobiotica · doi:10.3109/00498254.2014.991367 · Cited by 6
“Incubation of keto tanzisertib was carried out for 10 min at a cytosolic protein concentration of 0.1 mg/mL with cofactor NADPH or NADH (1 mM).”
BackgroundInfluentialPenning, T. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-046884-6.00408-5 · Cited by 6
Self-citationCui, T. R., Wang, X., Wu, Q., Zhong, Y., Wang, F., Zou, Y., Wang, Y., Jiang, S., & Ma, G. (2025) · Biomedicines · doi:10.3390/biomedicines13112584 · Cited by 5
Expressions of genes encoding steroidogenic enzymes and their role in prostate carcinogenesis
Frycz, B. A., & Jagodziński, P. P. (2014) · Journal of Medical Science · doi:10.20883/medical.e48 · Cited by 5
Liao, H., Zhong, Y., Zhou, D., Xie, Q., Zhang, Z., Wu, Y., Liu, S., Guo, W., Cui, L., & Wu, X. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110140 · Cited by 4
Isaacs, J. T., & Denmeade, S. R. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003353.014 · Cited by 4
The Aldo-Keto Reductase Superfamily
Penning, T. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64092-8 · Cited by 4
Self-citationSun, T., Sun, X., Wang, X., Guo, R. H., YU, Y., & Gao, L. (2023) · Biocell · doi:10.32604/biocell.2023.026229 · Cited by 3
Truncated Androgen Receptor Splice Variants in Prostate Cancer
Lonergan, P. E., & Tindall, D. J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6828-8_13 · Cited by 3
Balk, S. P. (2009) · Springer eBooks · doi:10.1007/978-0-387-69179-4_5 · Cited by 4
Exploring the roles of AKR1C1, AKR1C2, and AKR1C3 in the nervous system: Mechanisms and perspectives
Chen, X., Gan, L., Huang, Y., Wei, S. H., Wang, W., & Huang, Y. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115580 · Cited by 6
Stereoselective synthesis of allopregnanolone catalyzed by ketoreductase
Hou, Y., Lv, J., Guo, Y., Fang, J., Huang, C., Zhang, W., Jia, X., You, S., & Qin, B. Y. (2023) · Molecular Catalysis · doi:10.1016/j.mcat.2023.113433 · Cited by 2
Biason‐Lauber, A., Pandey, A. V., Miller, W. L., & Flück, C. E. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416006-4.00015-6 · Cited by 1
Expression of aldo-keto reductase family 1, member C14 during ovulation in the rat
Dam, P. T. M., Jang, Y.-J., Kim, J.-Y., Choi, S.-G., Park, J.-I., Seo, Y.-W., & Chun, S. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej17-0038 · Cited by 1
Evaluation of the clearance mechanism of non-CYP-mediated drug metabolism and DDI as a victim drug
Ghosal, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820018-6.00008-9 · Cited by 1
Crystallographic Studies of Steroid-Protein Interactions
Monzingo, A. F. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-14265-0_2 · Cited by 2
THE USE OF ESTROGEN RECEPTORS FOR EVALUATION OF PHYTOESTROGENS ACTIVITIES IN MAMMALS
Snochowski, M., & Romanowicz, K. (2003) · Polish Journal of Food and Nutrition Sciences · Cited by 3
Dietary risk factors for prostate cancer and benign prostatic hyperplasia
Ambrosini, G. L. (2007) · UWA Profiles and Research Repository (UWA)
Ligands of Estrogen Receptor β in Prostate and Brain
Muthusamy, S. (2014)
Robitaille, C. N. (2014) · EspaceINRS (National Institute for Scientific Research (Canada))
Zhang, B. (2014) · Corpus Université Laval (Université Laval)
Androgen biosynthesis in castration resistant
Penning, T. M. (2014)
Self-citationBordini, J., Morisi, F., Elia, A. R., Santambrogio, P., Pagani, A., Cucchiara, V., Ghia, P., Bellone, M., Briganti, A., Camaschella, C., et al. (2023) · doi:10.1158/1078-0432.c.6529337
Bordini, J., Morisi, F., Elia, A. R., Santambrogio, P., Pagani, A., Cucchiara, V., Ghia, P., Bellone, M., Briganti, A., Camaschella, C., et al. (2023) · doi:10.1158/1078-0432.c.6529337.v1
Steroidogenesis across species: aldo keto reductases in marsupials, fish and humans
Biason‐Lauber, A., Pandey, A. V., Miller, W. L., & Flück, C. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821424-4.00002-2
The Aldo-Keto Reductase Superfamily
Penning, T. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00010-3
Self-citationGuo, S.-S., Chen, Y.-Z., Liu, L.-T., Liu, R., Liang, Y., Wen, D., Jin, J., Tang, L., Mai, H.-Q., & Chen, Q. (2022) · Figshare · doi:10.6084/m9.figshare.20479614
Study of organochlorine pesticides metabolism and mode of action
Baratzhanova, G. (2024) · theses.fr (ABES) · doi:10.70675/dffbe2cfz087dz49ccza2aez3c4fa3099c0f
Kobori, Y., Nishitani, K., Yoshitomi, H., Murakami, A., Ichiyanagi, K., Yoshida, S., Tanaka, J., Kuriyama, S., Nakamura, S., Sakamoto, A., et al. (2026) · Journal of Orthopaedic Research® · doi:10.1002/jor.70279
“AKR1C2 encodes aldo‐ keto reductase family 1 member C2, which functions as a 3‐ketosteroid reductase that regulates hormone activity by converting androgens into inactive metabolites [42].”
Metadata
- Authors
- Rižner, T. L., Lin, H. K., Peehl, D. M., Steckelbroeck, S., Bauman, D. R., & Penning, T. M.
- Affiliations
- Department of Pharmacology, University of Pennsylvania School of Medicine (T.L.R., T.M.P., S.S., D.M.B.), Philadelphia, Pennsylvania 19104-6084
- University of Oklahoma Health Sciences Center (US)
- University of Pennsylvania (US)
- Stanford Medicine (US)
- Corresponding author
- Penning, Trevor M.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2003-07-01
- Volume
- 144
- Issue
- 7
- Pages
- 2922-2932
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2125072209
- Cited by
- 132
- References
- 33
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 7 · 2018: 3 · 2017: 5 · 2016: 10 · 2014: 10 · 2013: 10 · 2012: 3
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 97044)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK54925, DK-47015, R01DK054925, R01DK047015)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Aldose Reductase and Taurine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
- Keywords
- 3α-hydroxysteroid dehydrogenase, AKR1C2, aldo-keto reductase, androgen metabolism, dihydrotestosterone, 3α-androstanediol, 17β-hydroxysteroid dehydrogenase, androgen receptor activation, prostate cancer, PC-3 cells, LNCaP cells, glucuronidation
- MeSH terms
- Adenocarcinoma, Animals, Bone Neoplasms, Epithelial Cells, Humans, Hydroxysteroid Dehydrogenases, Isoenzymes, Male, Prostate, Prostatic Neoplasms, Dihydrotestosterone, Testosterone, Tumor Cells, Cultured, 17-Hydroxysteroid Dehydrogenases, Androstane-3,17-diol, Gene Expression Regulation, Enzymologic, COS Cells, 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific), In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.